

1 Michael J. McCue (Nevada Bar #6055)
2 Meng Zhong (Nevada Bar #12145)
3 LEWIS ROCA ROTHGERBER LLP
3993 Howard Hughes Parkway, Suite 600
4 Las Vegas, NV 89169-5996
(702) 949-8200 (phone)
5 (702) 949-8398 (facsimile)
mmccue@lrrlaw.com
mzhong@lrrlaw.com

6 Mark H. Izraelewicz (*pro hac vice* application to be filed)
7 Thomas I. Ross (*pro hac vice* application to be filed)
8 Kevin M. Flowers (*pro hac vice* application to be filed)
9 Amanda Antons (*pro hac vice* application to be filed)
MARSHALL, GERSTEIN & BORUN LLP
233 South Wacker Drive, 6300 Willis Tower
10 Chicago, IL 60606-6357
(312) 474-6300 (phone)
11 (312) 474-0448 (facsimile)
mizraelewicz@marshallip.com
12 tross@msrshallip.com
kflowers@marshallip.com
aantons@marshallip.com

13 Attorneys for Plaintiffs
14 SPECTRUM PHARMACEUTICALS, INC.
AND UNIVERSITY OF STRATHCLYDE

15
16 **UNITED STATES DISTRICT COURT**

17 **DISTRICT OF NEVADA**

18 SPECTRUM PHARMACEUTICALS, INC.)
and UNIVERSITY OF STRATHCLYDE,)
19)
Plaintiffs,)
20)
v.)
21)
AMNEAL PHARMACEUTICALS LLC)
22)
Defendants.)
23)

Case No.: 2:15-cv-01697

**COMPLAINT FOR PATENT
INFRINGEMENT**

24
25
26
27
28

1 Plaintiffs Spectrum Pharmaceuticals, Inc. (“Spectrum”) and University of Strathclyde
2 (“Strathclyde”) (collectively “Plaintiffs”) hereby allege for their Complaint against Defendant
3 Amneal Pharmaceuticals LLC (“Amneal”):

4 **NATURE OF THE ACTION**

5 1. This is an action for patent infringement under the patent laws of the United
6 States, 35 U.S.C. § 100 et seq., including 35 U.S.C. § 271(e)(2), and the Declaratory Judgment
7 Act, 28 U.S.C. §§ 2201 and 2202, arising from Amneal’s filing of an Abbreviated New Drug
8 Application (“ANDA”) under Section 505(j) of the Federal Food, Drug and Cosmetic Act, 21
9 U.S.C. § 355(j), seeking U.S. Food and Drug Administration (“FDA”) approval to market a
10 levoleucovorin product, which is a generic form of Spectrum’s pharmaceutical product Fusilev[®],
11 prior to the expiration of United States Patent No. 6,500,829 (“the ’829 patent”), which covers
12 Fusilev[®].

13 **THE PARTIES**

14 2. Spectrum is a Delaware corporation having its principal place of business at
15 11500 South Eastern Avenue, Suite 240, Henderson, Nevada 89052. Spectrum is engaged in the
16 business of research, development, manufacture, and sale of pharmaceutical products.

17 3. Strathclyde, incorporated by Royal Charter of Queen Elisabeth II, is a charitable
18 body registered in Scotland with registration number SC015263, having its principal place of
19 business at 16 Richmond Street, Glasgow G1 1XQ, Scotland, United Kingdom.

20 4. Upon information and belief, Amneal Pharmaceuticals LLC is a corporation
21 organized and existing under the laws of the State of Delaware, having a place of business at 400
22 Crossing Blvd., Bridgewater, NJ 08807.

23 5. Upon information and belief, Amneal markets, manufactures, distributes, and
24 sells generic drugs for use in the State of Nevada and throughout the United States.

25 **JURISDICTION AND VENUE**

26 6. This Court has subject-matter jurisdiction over this action pursuant to 28 U.S.C.
27 §§ 1331, 1338(a), 2201 and 2202.

28 7. This Court has personal jurisdiction over Amneal. Amneal has purposefully

1 conducted and continues to conduct business in this District, including by having availed itself of
2 the rights, protections, and benefits of Nevada law, such that it should reasonably anticipate
3 being hauled into court in this District.

4 8. On information and belief, Amneal applied for, and received a license from the
5 Nevada Board of Pharmacy to act as a pharmaceutical wholesaler in Nevada. On information and
6 belief, Amneal is currently a registered "Wholesaler" of drug products with the Nevada Board of
7 Pharmacy, and distributes drug products throughout the State of Nevada. Amneal has systematic
8 and continuous contacts with the State of Nevada, including, among other things, selling
9 pharmaceutical products to residents of Nevada, and to others with the intent that those products
10 are marketed and distributed in Nevada, and receiving significant revenue for the sale of those
11 products in Nevada.

12 9. Venue is proper in this District pursuant to 28 U.S.C. §§ 1391(c) and 1400(b).

13 **THE PATENT-IN-SUIT**

14 10. On December 31, 2002, the United States Patent and Trademark Office issued
15 U.S. Patent No. 6,500,829, entitled "Substantially Pure Diastereoisomers of Tetrahydrofolate
16 Derivatives." At the time of its issue, the '829 patent was assigned to Strathclyde. Strathclyde
17 currently holds title to the '829 patent. Strathclyde has exclusively licensed the '829 patent to
18 Spectrum. A copy of the '829 patent is attached hereto as Exhibit A.

19 11. On January 20, 2012, Plaintiffs filed suit against Sandoz Inc. ("Sandoz") in this
20 Court, Civil Action No. 12-cv-00111-GMN-NJK, alleging infringement of the '829 patent ("the
21 Sandoz case"). In response, Sandoz denied infringement and asserted that the claims of the '829
22 patent were invalid. On January 12, 2015, Sandoz stipulated that its proposed levoleucovorin
23 product infringe claims 1 and 2 of the '829 patent. A five-day bench trial related to the issue of
24 invalidity was held from January 12-20.

25 12. On February 20, 2015, this Court issued an order finding the asserted claims of
26 the '829 patent invalid for obviousness, and entered judgment in favor of Sandoz. On February
27 27, 2015 Plaintiffs filed a notice of appeal appealing this Court judgment of invalidity in the
28 Sandoz case to the U.S. Court of Appeals for the Federal Circuit ("Federal Circuit"). Pursuant to

1 Plaintiffs' motion to expedite the Federal Circuit appeal, briefing is complete and oral argument
2 was held on August 6, 2015.

3 **FUSILEV[®]**

4 13. Spectrum holds New Drug Application No. 20-140 (initially approved on March
5 7, 2008) (“the Fusilev[®] NDA”) approving Spectrum to market a levoleucovorin product as a
6 lyophilized powder in a 50 mg dosage strength, which is marketed by Spectrum under the trade
7 name Fusilev[®].

8 14. On April 20, 2011, the FDA granted Spectrum’s supplemental New Drug
9 Application approving Spectrum to market Fusilev[®] in 175 mg and 250 mg dosage strengths as
10 solutions for intravenous infusion (“the Fusilev[®] sNDA”).

11 15. On November 7, 2011, the FDA granted Fusilev[®] seven years of orphan-drug
12 exclusive approval pursuant to Section 527 of the Federal Food, Drug, and Cosmetic Act (21
13 U.S.C. § 360cc) for use in combination chemotherapy with 5-fluorouracil in the palliative
14 treatment of advanced metastatic adenocarcinoma of the colon and rectum.

15 16. Pursuant to 21 U.S.C. § 355(b)(1) and attendant FDA regulations, the ’829 patent
16 is listed in the FDA publication “Approved Drug Products with Therapeutic Equivalence
17 Evaluations” (“the Orange Book”) with respect to Fusilev[®].

18 **AMNEAL’S ANDA**

19 17. On information and belief, Amneal submitted an Abbreviated New Drug
20 Application, ANDA No. 207548, to the FDA, pursuant to 21 U.S.C. §§ 355(j), seeking approval
21 to market levoleucovorin calcium for injection, 10 mg/mL, 17.5 mL single-dose vial (“Amneal’s
22 ANDA”). The levoleucovorin vials described in Amneal’s ANDA are herein referred to as
23 “Amneal’s ANDA Product.”

24 18. On information and belief, Amneal’s ANDA refers to and relies upon the
25 Fusilev[®] sNDA and contains data that, according to Amneal, demonstrates the bioequivalence of
26 Amneal’s ANDA Product and Fusilev[®].

27 19. By filing Amneal’s ANDA, Amneal has necessarily represented to the FDA that
28 Amneal’s ANDA Product has the same active ingredient as Fusilev[®], has the same route of

1 administration, dosage form, and strength as Fusilev[®], is bioequivalent to Fusilev[®], and has the
2 same or substantially the same proposed labeling as Fusilev[®].

3 20. Spectrum received a letter from Amneal on or around August 4, 2015 (“Amneal’s
4 Notification”), stating that Amneal had included a certification in Amneal’s ANDA, pursuant to
5 21 U.S.C. §355(j)(2)(A)(vii)(IV), that the ’829 patent is invalid, unenforceable, or will not be
6 infringed by the commercial manufacture, use, or sale of Amneal’s ANDA Product.

7 21. This action is being brought within forty-five days from the date that Spectrum
8 received Amneal’s Notification.

9 **COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 6,500,829**

10 22. Plaintiffs reallege and incorporate by reference the allegations of paragraphs 1-21
11 of this Complaint.

12 23. The ’829 patent contains claims directed to, for example (claim 1), “A
13 pharmaceutical composition for therapeutic use which consists essentially of a therapeutically
14 effective amount sufficient for the treatment of human beings for methotrexate rescue or folate
15 deficiency, of a pharmaceutically acceptable compound which is a (6S) diastereoisomer selected
16 from the group consisting of (6S) leucovorin (5-formyl-(6S)-tetrahydrofolic acid) and
17 pharmaceutically acceptable salts and esters of (6S) leucovorin; wherein the compound consists
18 of a mixture of (6S) and (6R) diastereoisomers and consists of at least 92% by weight of the (6S)
19 diastereoisomer, the balance of said compound consisting of the (6R) diastereoisomer; in
20 combination with a pharmaceutically acceptable carrier. Amneal has committed an act of
21 infringement under 35 U.S.C. § 271(e)(2)(A) by submitting Amneal’s ANDA, by which Amneal
22 seeks approval from the FDA to engage in the commercial manufacture, use, offer to sell, sale, or
23 importation of Amneal’s Product prior to the expiration of the ’829 patent.

24 24. Amneal’s commercial manufacture, use, offer to sell, or sale of Amneal’s ANDA
25 Product within the United States, or importation of Amneal’s Product into the United States,
26 during the term of the ’829 patent would further infringe one or more claims of the ’829 patent
27 under 35 U.S.C. §§ 271(a), (b), and/or (c).

28 25. Amneal’s Notification admits infringement of claims 1 and 2 of the ’829 patent.

1 26. Amneal's filing of Amneal's ANDA and its intention to engage in the commercial
2 manufacture, use, offer to sell, sale, or importation of Amneal's Product upon receiving FDA
3 approval creates an actual case or controversy with respect to infringement of the '829 patent.

4 27. Plaintiffs are entitled to the relief provided by 35 U.S.C. § 271(e)(4), including an
5 order of this Court that the effective date of any approval relating to Amneal's ANDA shall not
6 be earlier than March 7, 2022, the current expiration date of the '829 patent, or any later
7 expiration date to which Plaintiffs become entitled.

8 28. This is an exceptional case, and Plaintiffs are entitled to an award of attorneys'
9 fees, under 35 U.S.C. § 285.

10 **REQUEST FOR RELIEF**

11 WHEREFORE, Plaintiffs request that this Court grant the following relief:

12 A. A declaration that the '829 patent is valid and enforceable;

13 B. A declaration that by filing Amneal's ANDA, Amneal has infringed one or more
14 claims of the '829 patent under 35 U.S.C. § 271(e)(2)(A);

15 C. A declaration that one or more claims of the '829 patent would be infringed by
16 the manufacture, use, offer for sale, or sale of Amneal's ANDA Product within the United States,
17 or by importation of Amneal's ANDA Product into the United States;

18 D. An Order preliminarily and permanently enjoining Amneal, its officers, agents,
19 servants, and employees, and those persons in active concert or participation with any of them,
20 from manufacturing, using, offering to sell, or selling Amneal's ANDA Product within the
21 United States, or importing Amneal's ANDA Product into the United States, prior to the
22 expiration of the '829 patent (including any extensions thereof);

23 E. An Order prohibiting Amneal, its officers, agents, servants, and employees, and
24 those persons in active concert or participation with any of them, from seeking, obtaining, or
25 maintaining approval of Amneal's ANDA, prior to the expiration of the '829 patent (including
26 any extensions thereof);

27 F. A declaration that the effective date of any approval of Amneal's ANDA under §
28 505(j) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 355(j)) shall not be earlier than

1 the expiration date of the '829 patent (including any extensions thereof);

2 G. A judgment awarding Plaintiffs damages or other monetary relief if Amneal
3 commercially manufactures, uses, offers to sell, or sells Amneal's ANDA Product within the
4 United States, or imports Amneal's ANDA Product into the United States, prior to the expiration
5 of the '829 patent (including any extensions thereof), and that any such damages or monetary
6 relief be trebled and awarded to Plaintiffs with prejudgment interest;

7 H. A declaration that this is an exceptional case and a judgment awarding Plaintiffs
8 their reasonable attorneys' fees incurred in this action pursuant to 35 U.S.C. § 285 and 271(e)(4);

9 I. Reasonable filing fees, costs, and expenses incurred by Plaintiffs in this action;
10 and

11 J. Such further and other relief as this Court deems just and proper.

12 Dated: September 3, 2015.

Respectfully submitted,

13 LEWIS ROCA ROTHGERBER LLP

14 By: /s/ Meng Zhong

15 Michael J. McCue (Nevada Bar #6055)
16 Meng Zhong (Nevada Bar #12145)
17 3993 Howard Hughes Parkway, Suite 600
18 Las Vegas, NV 89169-5996
19 (702) 949-8200 (phone)
20 (702) 949-8398 (facsimile)
21 mmccue@lrrlaw.com
22 mzhong@lrrlaw.com

23 Mark H. Izraelewicz (*pro hac vice* application to be filed)
24 Thomas I. Ross (*pro hac vice* application to be filed)
25 Kevin M. Flowers (*pro hac vice* application to be filed)
26 Amanda Antons (*pro hac vice* application to be filed)
27 MARSHALL, GERSTEIN & BORUN LLP
28 233 South Wacker Drive
6300 Willis Tower
Chicago, IL 60606-6357
(312) 474-6300 (phone)
(312) 474-0448 (facsimile)
mizraelewicz@marshallip.com
tross@marshallip.com
kflowers@marshallip.com
aantons@marshallip.com

Attorneys for Plaintiffs
SPECTRUM PHARMACEUTICALS, INC.
AND UNIVERSITY OF STRATHCLYDE